HOOKIPA Pharma Gains 51% After Hours on Amended Agreement with Gilead

Seeking Alpha2022-02-16

HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

KyawGyee
2022-02-16
KyawGyee
like pls
sfleong1
2022-02-16
sfleong1
Like n comment
HOTBE
2022-02-16
HOTBE
Awesome
大赢家 BIG WINNER
2022-02-16
大赢家 BIG WINNER
👌
bostonxsgp
2022-02-16
bostonxsgp
Interesting. Please like

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2211586046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-16 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2211586046","market":"us","top_or_hot":-1,"title":"HOOKIPA Pharma Gains 51% After Hours on Amended Agreement with Gilead","media":"Seeking Alpha","content":"<div>\n<p>HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV ...</p>\n\n<a href=\"https://seekingalpha.com/news/3800476-hookipa-pharma-gains-51-after-hours-on-amended-agreement-with-gilead\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOOKIPA Pharma Gains 51% After Hours on Amended Agreement with Gilead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOOKIPA Pharma Gains 51% After Hours on Amended Agreement with Gilead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3800476-hookipa-pharma-gains-51-after-hours-on-amended-agreement-with-gilead><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV ...</p>\n\n<a href=\"https://seekingalpha.com/news/3800476-hookipa-pharma-gains-51-after-hours-on-amended-agreement-with-gilead\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://seekingalpha.com/news/3800476-hookipa-pharma-gains-51-after-hours-on-amended-agreement-with-gilead","article_id":"2211586046","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2211586046","pubTimestamp":1644967695,"sourceInfo":null,"weMediaInfo":null,"summary":"HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement wit","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","BK4505":"高瓴资本持仓","HOOK":"Hookipa Pharma Inc","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4566":"资本集团","BK4532":"文艺复兴科技持仓"},"translate_title":"HOOKIPA Pharma在与Gilead的修订协议后几个小时内上涨51%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1,"HOOK":1},"content_text":"HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV regimen.In 2018, Gilead (GILD) licensed exclusive right to HOOKIPA's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus. Under that pact, the companies would collaborate through a joint research phase, after which Gilead (GILD) had rights for further development.Under the amended agreement, HOOKIPA (HOOK) is responsible for advancing the HIV program through the end of a Phase 1b clinical trial, with funding from Gilead (GILD) via an upfront payment. After the phase 1b trial is completed, Gilead (GILD) has the exclusive right to assume further development. The hepatitis B virus part of the agreement is unchanged.HOOKIPA (HOOK) will receive a $15 million upfront fee with the amended agreement. It will also receive a $5M equity payment investment from Gilead (GILD) and up to $30M in additional equity financing.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9095423864,"gmtCreate":1644975455541,"gmtModify":1676533982266,"author":{"id":"4090595486982830","authorId":"4090595486982830","name":"KyawGyee","avatar":"https://static.tigerbbs.com/fdcba8de8d5ea791b5d78858d5e024b4","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1},"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095423864","repostId":2211586046,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095572048,"gmtCreate":1644968616666,"gmtModify":1676533980511,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095572048","repostId":2211586046,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095578776,"gmtCreate":1644968515740,"gmtModify":1676533980476,"author":{"id":"3576325295778787","authorId":"3576325295778787","name":"HOTBE","avatar":"https://static.tigerbbs.com/4f535d0d25c5b9833a0f75cd652fbbcd","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Awesome&nbsp;","listText":"Awesome&nbsp;","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095578776","repostId":2211586046,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095573545,"gmtCreate":1644968339858,"gmtModify":1676533980426,"author":{"id":"4091244300202810","authorId":"4091244300202810","name":"大赢家 BIG WINNER","avatar":"https://static.tigerbbs.com/59a385c79fcea7906bfceb7d654366cf","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"👌","listText":"👌","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095573545","repostId":2211586046,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095547974,"gmtCreate":1644967907729,"gmtModify":1676533980347,"author":{"id":"3584157491931754","authorId":"3584157491931754","name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Interesting. Please like","listText":"Interesting. Please like","text":"Interesting. Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095547974","repostId":2211586046,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":85,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2211586046"}